Previous Article | Next Article ![]()
Infection and Immunity, February 2006, p. 1091-1096, Vol. 74, No. 2
0019-9567/06/$08.00+0 doi:10.1128/IAI.74.2.1091-1096.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts,1 Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts,2 Institute of Medical Microbiology, University of Münster, Münster, Germany,3 Division of Infectious Diseases and International Health, University of Virginia Health System, Charlottesville, Virginia4
Received 31 May 2005/ Returned for modification 22 July 2005/ Accepted 9 November 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
-hemolysin, protein A, and thermonuclease) (15, 33) and yet has an increased ability to produce others (e.g., clumping factor and fibronectin-binding protein) (15, 30). The menD mutant also recapitulates the SCV phenotype and is highly resistant to the cationic antimicrobial peptide thrombin-induced platelet microbicidal protein 1 (2). Recently, we and others have used the nematode Caenorhabditis elegans to model host/pathogen relationships in pathogenic microbes and to assess the contribution of specific gene products to virulence (recently reviewed in reference 26). In this study, the hemB and menD mutants as well as clinical isolates with the SCV phenotype were tested in the C. elegans infection model in order to obtain more information on the pathogenic fitness of these variants and to better characterize C. elegans-S. aureus host/pathogen interactions.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Bacterial strains. Bacterial strains used in this study are listed in Table 1. SCVs cultured from clinical specimens were recovered from patients with chronic and recurrent infections such as chronic osteomyelitis (isolates A22616/3 and A22223II). SCVs were identified as previously reported (14, 31). Isolates were confirmed to be S. aureus by testing for the S. aureus-specific nuc and coa genes by PCR (7). One SCV isolate (isolate A22616/3) was found to be menadione auxotrophic following testing on chemically defined medium as previously described; the other SCV isolate (isolate A22223II) was hemin auxotrophic. The corresponding isolates with normal phenotypes (isolates A22616/5 and A22223I) were recovered in a parallel or sequential culture from the same patient, respectively. SmaI digests of total bacterial DNA were resolved with the use of pulsed-field gel electrophoresis (PFGE) as previously described (12), demonstrating that the strains with the normal and SCV phenotypes recovered from the same patient were clonal.
|
The construction of the menD mutant DB24 and repaired menD mutant DB25 in S. aureus strain 8325-4 by allelic exchange has been described elsewhere previously (2). Phage transduction of the menD mutation into S. aureus strain COL has been previously reported (34).
Bacterial strains were maintained at 70°C in tryptic soy (TS) broth containing 15% glycerol. S. aureus strains were grown at 37°C with aeration in TS broth that was supplemented with 2.5 µg/ml erythromycin or 10 µg/ml chloramphenicol, if appropriate.
C. elegans survival assays. C. elegans killing assays were performed as previously described (27), with the following modifications. For standard assay plates, 10 µl of a culture grown overnight was spread onto 3.5-cm-diameter plates containing TS agar supplemented with 5 µg/ml nalidixic acid and additional antibiotics, as appropriate, and incubated at 37°C for 6 h. For "spotted-lawn" assay plates, 3 ml (for SCVs) or 1 ml (for wild-type or complemented/repaired strains) of a 24-h culture was pelleted by centrifugation, decanted of the supernatant, and resuspended in 100 µl TS medium. Fifty microliters of the concentrated bacteria was then spotted onto a TS agar plate supplemented with nalidixic acid and additional antibiotics, as appropriate. The spotted-lawn assay plates were used for nematode survival assays once the lawns had dried, usually within 30 to 60 min.
Hermaphrodite nematodes of the 4th larval (L4) stage were transferred from their normal food source to the tested strain, and their survival was monitored over time at 25°C. Approximately 20 to 25 nematodes were transferred to each plate, and all experiments were conducted in triplicate and repeated at least three times. Nematodes were classified as dead when they failed to respond to touch and pharyngeal pumping was no longer observed. Worms that died as a result of crawling off the plate were censored from the analysis. For each killing assay, nematode survival was calculated by the Kaplan-Meier method, and survival differences were tested for significance by use of the log rank test (GraphPad Prism, version 3.0). P values of <0.05 were considered statistically significant. Nematode alimentary tracts were examined by differential interference contrast microscopy with a standard Axioplan2 microscope fitted with Normarski optics (Zeiss) using established methodologies (29).
| RESULTS |
|---|
|
|
|---|
We were concerned that slow growth of the SCVs on standard assay plates might bias the results towards an attenuated phenotype due to the thin lawns produced on these plates. It was conceivable that increased worm survival on the SCV plates could be the result of decreased exposure to the pathogen. Therefore, nematode survival assays were performed with plates that were seeded with concentrated bacteria to insure that differences in nematode survival were not simply due to limited exposure to pathogenic bacteria on the SCV plates (see Materials and Methods). Using this modified "spotted-lawn" nematode survival assay, the clinical SCV strains A22223II and A22616/3 remained significantly less virulent for nematodes than parental strains A22223I and A22616/5, respectively (Fig. 1). Of note, several (usually 5 to 20) large colony revertants would typically arise per plate on the SCV lawns during the course of each experiment.
|
|
Next, we sought to ascertain whether genetically defined menadione-auxotrophic SCV mutants are attenuated for virulence in worm killing, similar to clinical SCV strain A22616/3. As shown in Fig. 3A, menD mutant strain DB24 was highly attenuated in worm killing compared to the parental S. aureus strain 8325-4, while the menD-repaired strain DB25 was partially restored in virulence. The reduced virulence of menD SCVs was confirmed in S. aureus strain COL, as shown in Fig. 3B. Of note, no large colony revertants were observed on the lawns of the site-directed hemB and menD mutants.
|
|
| DISCUSSION |
|---|
|
|
|---|
While it may not be feasible or accurate to test clinically derived isolates with SCV phenotypes in traditional animal models due to their inherent phenotypic instability and lack of genetic definition, the C. elegans infection model offers a simple and rapid means to evaluate the virulence potential of clinical SCVs and to compare these isolates with hemB and menD mutants mimicking the SCV phenotype. The SCV phenotype can easily be tracked during the assay, and thus, the influence of reversion to the normal phenotype during the course of the experiment can be monitored. In fact, some reversion to large colony growth did occur during the later stages of the assays with clinical SCV isolates in the present study, but this reversion did not appear to significantly impact the assay results, as judged by parallel assays using engineered hemB and menD mutants. In addition, virulence may be assessed without the external influence of hemin on hemin-auxotrophic SCVs, in contrast to the many mammalian infection models.
We found that clinical SCVs that were auxotrophic for hemin or menadione were less virulent in this invertebrate infection model and that the reduced virulence could not be ascribed to reduced exposure to the pathogen. Moreover, hemB and menD mutants were similarly less virulent than isogenic parental and complemented strains, confirming the importance of bacterial respiration for virulence in this infection model system. Reduced virulence of the SCV strains was not the result of an impaired ability to colonize the nematode digestive tract. We have previously observed that other S. aureus virulence-attenuated mutants demonstrate comparable levels of colonization of the nematode digestive tract (5, 27). In contrast, we have recently noted that impaired biofilm formation reduces the ability of Staphylococcus epidermidis to colonize the nematode digestive tract (J. Begun, S. Calderwood, F. Ausubel, and C. Sifri, unpublished observations).
The reduced virulence of the hemB mutants observed in the C. elegans infection model stands in marked contrast with observations made with the hemB SCVs in experimental septic arthritis and endocarditis. However, this reduced virulence capacity is congruent with the clinical characteristics of SCV infection since these organisms are typically recovered in patients with chronic, indolent, and/or relapsing disease. The reduced virulence of the menD SCV in experimental endocarditis suggests that endogenous hemin does not complement the SCV defect of this mutant in this experimental model, in contrast to the hemB mutant. We and others have previously observed that S. aureus tricarboxylic acid (TCA) cycle mutants are attenuated for virulence in C. elegans-based and other in vivo systems (1, 5, 9, 18). In S. aureus, the TCA cycle is repressed during exponential growth, leading to the accumulation of acetyl coenzyme A (acetyl-CoA). Depletion of glucose via glycolysis during exponential growth triggers entry into post-exponential-phase growth and acetyl-CoA catabolism. Therefore, flux of acetyl-CoA through the TCA cycle serves as the primary source of energy for the production of secreted virulence factors (28). The loss of a functional electron transport system in hemin- and menadione-auxotrophic SCVs also results in greatly reduced extracellular protein production, including
-hemolysin (15, 33). The genes for several S. aureus exoproteins, such as hla (
-hemolysin), have been shown to be important for nematode-mediated killing (27). Therefore, we hypothesize that the reduced production of
-hemolysin and perhaps other virulence products in the SCV strains due to the loss of oxidative phosphorylation leads to reduced virulence in nematodes.
Another notable difference between nematode and mammalian infection models is the importance of cell surface adhesins. In contrast to disease in vertebrates, at least 10 different staphylococcal surface proteins and sortase A (srtA), a gene required for their proper display, do not appear to contribute to nematode colonization or disease (1). Interestingly, hemB mutants exhibit increased expression of surface adhesins such as clumping factor and fibronectin-binding proteins (30). Thus, increased adhesion production in hemB and conceivably other SCV mutants may mitigate the effect of reduced production of other virulence factors in some mammalian infection models but would not be predicted to alter disease in the nematode.
This is the first in vivo study to assess the virulence capacity of clinical S. aureus SCV isolates as well as hemB and menD mutants that recapitulate the SCV phenotype. We conclude that clinical SCVs and hemB and menD mutants are less virulent in this simple invertebrate model of acute S. aureus infection. The reduced virulence may be a reflection of reduced exoprotein production due to defects in oxidative phosphorylation. Inhibition of bacterial respiration as a virulence-inhibiting mechanism will be the subject of further research.
| ACKNOWLEDGMENTS |
|---|
This work was supported by NIAID grant K08 AI053677 and by a Harvard Medical School Center for AIDS Research Feasibility Project grant to C.D.S., by a research grant from Aventis Pharmaceuticals to S.B.C., and by a research grant from BMBF (Pathogenomic) to C.V.E.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
| 1. | Bae, T., A. K. Banger, A. Wallace, E. M. Glass, F. Aslund, O. Schneewind, and D. M. Missiakas. 2004. Staphylococcus aureus virulence genes identified by bursa aurealis mutagenesis and nematode killing. Proc. Natl. Acad. Sci. USA 101:12312-12317. |
| 2. | Bates, D. M., C. von Eiff, P. J. McNamara, G. Peters, M. R. Yeaman, A. S. Bayer, and R. A. Proctor. 2003. Staphylococcus aureus menD and hemB mutants are as infective as the parent strains, but the menadione biosynthetic mutant persists within the kidney. J. Infect. Dis. 187:1654-1661.[CrossRef][Medline] |
| 3. | Baumert, N., C. von Eiff, F. Schaaff, G. Peters, R. A. Proctor, and H. G. Sahl. 2002. Physiology and antibiotic susceptibility of Staphylococcus aureus small colony variants. Microb. Drug Resist. 8:253-260.[CrossRef][Medline] |
| 4. | Beenken, K. E., J. S. Blevins, and M. S. Smeltzer. 2003. Mutation of sarA in Staphylococcus aureus limits biofilm formation. Infect. Immun. 71:4206-4211. |
| 5. | Begun, J., C. D. Sifri, S. Goldman, S. B. Calderwood, and F. M. Ausubel. 2005. Staphylococcus aureus virulence factors identified by using a high-throughput Caenorhabditis elegans-killing model. Infect. Immun. 73:872-877. |
| 6. | Blevins, J. S., K. E. Beenken, M. O. Elasri, B. K. Hurlburt, and M. S. Smeltzer. 2002. Strain-dependent differences in the regulatory roles of sarA and agr in Staphylococcus aureus. Infect. Immun. 70:470-480. |
| 7. | Brakstad, O. G., K. Aasbakk, and J. A. Maeland. 1992. Detection of Staphylococcus aureus by polymerase chain reaction amplification of the nuc gene. J. Clin. Microbiol. 30:1654-1660. |
| 8. | Brenner, S. 1974. The genetics of Caenorhabditis elegans. Genetics 77:71-94. |
| 9. | Coulter, S. N., W. R. Schwan, E. Y. Ng, M. H. Langhorne, H. D. Ritchie, S. Westbrock-Wadman, W. O. Hufnagle, K. R. Folger, A. S. Bayer, and C. K. Stover. 1998. Staphylococcus aureus genetic loci impacting growth and survival in multiple infection environments. Mol. Microbiol. 30:393-404.[CrossRef][Medline] |
| 10. | Duthie, E. S., and L. L. Lorenz. 1952. Staphylococcal coagulase: mode of action and antigenicity. J. Gen. Microbiol. 6:95-107.[Medline] |
| 11. | Garsin, D. A., J. M. Villanueva, J. Begun, D. H. Kim, C. D. Sifri, S. B. Calderwood, G. Ruvkun, and F. M. Ausubel. 2003. Long-lived C. elegans daf-2 mutants are resistant to bacterial pathogens. Science 300:1921. |
| 12. | Ichiyama, S., M. Ohta, K. Shimokata, N. Kato, and J. Takeuchi. 1991. Genomic DNA fingerprinting by pulsed-field gel electrophoresis as an epidemiological marker for study of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 29:2690-2695. |
| 13. | Jonsson, I. M., C. von Eiff, R. A. Proctor, G. Peters, C. Ryden, and A. Tarkowski. 2003. Virulence of a hemB mutant displaying the phenotype of a Staphylococcus aureus small colony variant in a murine model of septic arthritis. Microb. Pathog. 34:73-79.[CrossRef][Medline] |
| 14. | Kahl, B., M. Herrmann, A. S. Everding, H. G. Koch, K. Becker, E. Harms, R. A. Proctor, and G. Peters. 1998. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J. Infect. Dis. 177:1023-1029.[Medline] |
| 15. | Kohler, C., C. von Eiff, G. Peters, R. A. Proctor, M. Hecker, and S. Engelmann. 2003. Physiological characterization of a heme-deficient mutant of Staphylococcus aureus by a proteomic approach. J. Bacteriol. 185:6928-6937. |
| 16. | Koo, S. P., M. R. Yeaman, and A. S. Bayer. 1996. Staphylocidal action of thrombin-induced platelet microbicidal protein is influenced by microenvironment and target cell growth phase. Infect. Immun. 64:3758-3764.[Abstract] |
| 17. | Lewis, J. A., and J. T. Fleming. 1995. Basic culture methods, p. 3-29. In H. F. Epstein and D. C. Shakes (ed.), Caenorhabditis elegans: modern biological analysis of an organism, vol. 48. Academic Press, San Diego, Calif. |
| 18. | Mei, J. M., F. Nourbakhsh, C. W. Ford, and D. W. Holden. 1997. Identification of Staphylococcus aureus virulence genes in a murine model of bacteraemia using signature-tagged mutagenesis. Mol. Microbiol. 26:399-407.[CrossRef][Medline] |
| 19. | Proctor, R. A., D. M. Bates, and P. J. McNamara. 2001. Electron transport-deficient Staphylococcus aureus small-colony variants as emerging pathogens, p. 95-110. In W. M. Scheld, W. A. Craig, and J. M. Hughes (ed.), Emerging infections 5. ASM Press, Washington, D.C. |
| 20. | Proctor, R. A., B. Kahl, C. von Eiff, P. E. Vaudaux, D. P. Lew, and G. Peters. 1998. Staphylococcal small colony variants have novel mechanisms for antibiotic resistance. Clin. Infect. Dis. 27(Suppl. 1):S68-S74. |
| 21. | Proctor, R. A., and G. Peters. 1998. Small colony variants in staphylococcal infections: diagnostic and therapeutic implications. Clin. Infect. Dis. 27:419-422.[Medline] |
| 22. | Proctor, R. A., P. van Langevelde, M. Kristjansson, J. N. Maslow, and R. D. Arbeit. 1995. Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus. Clin. Infect. Dis. 20:95-102.[Medline] |
| 23. | Rigoulay, C., J. M. Entenza, D. Halpern, E. Widmer, P. Moreillon, I. Poquet, and A. Gruss. 2005. Comparative analysis of the roles of HtrA-like surface proteases in two virulent Staphylococcus aureus strains. Infect. Immun. 73:563-572. |
| 24. | Sadowska, B., A. Bonar, C. von Eiff, R. A. Proctor, M. Chmiela, W. Rudnicka, and B. Rozalska. 2002. Characteristics of Staphylococcus aureus, isolated from airways of cystic fibrosis patients, and their small colony variants. FEMS Immunol. Med. Microbiol. 32:191-197.[CrossRef][Medline] |
| 25. | Seifert, H., H. Wisplinghoff, P. Schnabel, and C. von Eiff. 2003. Small colony variants of Staphylococcus aureus and pacemaker-related infection. Emerg. Infect. Dis. 9:1316-1318.[Medline] |
| 26. | Sifri, C. D., J. Begun, and F. M. Ausubel. 2005. The worm has turnedmicrobial virulence modeled in Caenorhabditis elegans. Trends Microbiol. 13:119-127.[CrossRef][Medline] |
| 27. | Sifri, C. D., J. Begun, F. M. Ausubel, and S. B. Calderwood. 2003. Caenorhabditis elegans as a model host for Staphylococcus aureus pathogenesis. Infect. Immun. 71:2208-2217. |
| 28. | Somerville, G. A., M. S. Chaussee, C. I. Morgan, J. R. Fitzgerald, D. W. Dorward, L. J. Reitzer, and J. M. Musser. 2002. Staphylococcus aureus aconitase inactivation unexpectedly inhibits post-exponential-phase growth and enhances stationary-phase survival. Infect. Immun. 70:6373-6382. |
| 29. | Sulston, J., and J. Hodgkin. 1998. Methods, p. 587-606. In W. B. Wood (ed.), The nematode Caenorhabditis elegans. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 30. | Vaudaux, P., P. Francois, C. Bisognano, W. L. Kelley, D. P. Lew, J. Schrenzel, R. A. Proctor, P. J. McNamara, G. Peters, and C. Von Eiff. 2002. Increased expression of clumping factor and fibronectin-binding proteins by hemB mutants of Staphylococcus aureus expressing small colony variant phenotypes. Infect. Immun. 70:5428-5437. |
| 31. | von Eiff, C., K. Becker, D. Metze, G. Lubritz, J. Hockmann, T. Schwarz, and G. Peters. 2001. Intracellular persistence of Staphylococcus aureus small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with Darier's disease. Clin. Infect. Dis. 32:1643-1647.[CrossRef][Medline] |
| 32. | von Eiff, C., D. Bettin, R. A. Proctor, B. Rolauffs, N. Lindner, W. Winkelmann, and G. Peters. 1997. Recovery of small colony variants of Staphylococcus aureus following gentamicin bead placement for osteomyelitis. Clin. Infect. Dis. 25:1250-1251.[Medline] |
| 33. | von Eiff, C., C. Heilmann, R. A. Proctor, C. Woltz, G. Peters, and F. Gotz. 1997. A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly. J. Bacteriol. 179:4706-4712. |
| 34. | von Eiff, C., P. J. McNamara, K. Becker, D. Bates, X.-H. Lei, M. Ziman, B. R. Bochner, G. Peters, and R. A. Proctor. 2006. Phenotype microarray profiling of Staphylococcus aureus menD and hemB mutants with small colony variant phenotype. J. Bacteriol., 188:687-693. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|